Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Children's Hospital
mi
from
Pittsburgh, PA
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Children's Hospital
mi
from
Pittsburgh, PA
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Children's Nutrition Research Center, Baylor College of Medicine
mi
from
Houston, TX
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Children's Nutrition Research Center, Baylor College of Medicine
mi
from
Houston, TX
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Children's Hospital - Boston
mi
from
Boston, MA
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Children's Hospital - Boston
mi
from
Boston, MA
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Indiana University Adult Psychiatry Clinic
mi
from
Indianapolis, IN
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Indiana University Adult Psychiatry Clinic
mi
from
Indianapolis, IN
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Siteman Cancer Center
mi
from
St. Louis, MO
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Siteman Cancer Center
mi
from
St. Louis, MO
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Baylor School of Medicine
mi
from
Houston, TX
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Baylor School of Medicine
mi
from
Houston, TX
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Children's Hospital and Regional Medical Center - Seattle
mi
from
Seattle, WA
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Status: Archived
Updated: 1/1/1970
Children's Hospital and Regional Medical Center - Seattle
mi
from
Seattle, WA
Donor Stem Cell Transplant After Total-Body Irradiation in Treating Patients With Relapsed or Refractory Hematologic Cancer or Acute Myeloid Leukemia or Acute Lymphocytic Leukemia in Complete Remission
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation
Status: Archived
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Donor Stem Cell Transplant After Total-Body Irradiation in Treating Patients With Relapsed or Refractory Hematologic Cancer or Acute Myeloid Leukemia or Acute Lymphocytic Leukemia in Complete Remission
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation
Status: Archived
Updated: 1/1/1970
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
Kootenai Cancer Center
mi
from
Coeur d'Alene, ID
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Kootenai Cancer Center
mi
from
Coeur d'Alene, ID
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
Rush University Medical Center
mi
from
Chicago, IL
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Rush University Medical Center
mi
from
Chicago, IL
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
Owsley Brown Frazier Cancer Center
mi
from
Louisville, KY
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Owsley Brown Frazier Cancer Center
mi
from
Louisville, KY
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
Overton Brooks VA Medical Center
mi
from
Shreveport, LA
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Overton Brooks VA Medical Center
mi
from
Shreveport, LA
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
Frontier Cancer Center and Blood Institute
mi
from
Billings, MT
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Frontier Cancer Center and Blood Institute
mi
from
Billings, MT
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
New York University Hospital
mi
from
New York, NY
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
New York University Hospital
mi
from
New York, NY
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
Providence Cancer Center
mi
from
Portland, OR
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Providence Cancer Center
mi
from
Portland, OR
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
The West Clinic (ACORN)
mi
from
Memphis, TN
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
The West Clinic (ACORN)
mi
from
Memphis, TN
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
Gundersen Lutheran
mi
from
La Crosse, WI
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Gundersen Lutheran
mi
from
La Crosse, WI
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Providence Cancer Center at Providence Hospital
mi
from
Mobile, AL
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Updated: 1/1/1970
Providence Cancer Center at Providence Hospital
mi
from
Mobile, AL
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Alaska Regional Hospital Cancer Center
mi
from
Anchorage, AK
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Updated: 1/1/1970
Alaska Regional Hospital Cancer Center
mi
from
Anchorage, AK
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Providence Portland Cancer Center
mi
from
Portland, OR
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Updated: 1/1/1970
Providence Portland Cancer Center
mi
from
Portland, OR
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
mi
from
Ft. Smith, AR
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Updated: 1/1/1970
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
mi
from
Ft. Smith, AR
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Alta Bates Comprehensive Cancer Center
mi
from
Berkeley, CA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Updated: 1/1/1970
Alta Bates Comprehensive Cancer Center
mi
from
Berkeley, CA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Providence Saint-Joseph Medical Center
mi
from
Burbank, CA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Updated: 1/1/1970
Providence Saint-Joseph Medical Center
mi
from
Burbank, CA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Peninsula Medical Center
mi
from
Burlingame, CA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Updated: 1/1/1970
Peninsula Medical Center
mi
from
Burlingame, CA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
North Bay Cancer Center
mi
from
Fairfield, CA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Updated: 1/1/1970
North Bay Cancer Center
mi
from
Fairfield, CA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
California Pacific Medical Center - California Campus
mi
from
San Francisco, CA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Updated: 1/1/1970
California Pacific Medical Center - California Campus
mi
from
San Francisco, CA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Sutter Health - Western Division Cancer Research Group
mi
from
San Rafael, CA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Updated: 1/1/1970
Sutter Health - Western Division Cancer Research Group
mi
from
San Rafael, CA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Sutter Solano Medical Center
mi
from
Vallejo, CA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Updated: 1/1/1970
Sutter Solano Medical Center
mi
from
Vallejo, CA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
mi
from
Hartford, CT
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Updated: 1/1/1970
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
mi
from
Hartford, CT
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Updated: 1/1/1970
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
CCOP - Atlanta Regional
mi
from
Atlanta, GA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Updated: 1/1/1970
CCOP - Atlanta Regional
mi
from
Atlanta, GA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Northside Hospital
mi
from
Atlanta, GA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Updated: 1/1/1970
Northside Hospital
mi
from
Atlanta, GA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Saint Joseph's Hospital of Atlanta
mi
from
Atlanta, GA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Updated: 1/1/1970
Saint Joseph's Hospital of Atlanta
mi
from
Atlanta, GA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Piedmont Hospital
mi
from
Atlanta, GA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Updated: 1/1/1970
Piedmont Hospital
mi
from
Atlanta, GA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
WellStar Cobb Hospital
mi
from
Austell, GA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Updated: 1/1/1970
WellStar Cobb Hospital
mi
from
Austell, GA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
John B. Amos Cancer Center
mi
from
Columbus, GA
Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma
Central Lymphoma Serum Repository Protocol
Status: Archived
Updated: 1/1/1970
John B. Amos Cancer Center
mi
from
Columbus, GA